Ocular Therapeutix (OCUL) Enterprise Value (2013 - 2026)

Ocular Therapeutix's Enterprise Value history runs 14 years deep, the most recent figure standing at -$666.7 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 90.66% year-over-year to -$666.7 million in Q1 2026; TTM through Mar 2026 was -$666.7 million, a 90.66% decrease from a year earlier, with the FY2025 full-year figure at -$737.1 million, down 87.98% from the prior year.
• Enterprise Value grew to -$666.7 million in Q1 2026 per OCUL's latest filing, from -$737.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$66.6 million in Q2 2023 and bottomed at -$737.1 million in Q4 2025.
• The 5-year median for Enterprise Value is -$344.8 million (2025), against an average of -$306.3 million.
• Across the five-year window, Enterprise Value soared 50.49% in 2023 and slumped 590.16% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$102.3 million in 2022, then slumped by 91.55% to -$196.0 million in 2023, then sank by 100.1% to -$392.1 million in 2024, then tumbled by 87.98% to -$737.1 million in 2025, then increased by 9.55% to -$666.7 million in 2026.
• Per Business Quant, the three latest OCUL Enterprise Value figures stand at -$666.7 million (Q1 2026), -$737.1 million (Q4 2025), and -$344.8 million (Q3 2025).